Ghassan K. Abou-Alfa, MD, on HCC: Results From the CELESTIAL Trial

2018 Gastrointestinal Cancers Symposium

Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).

Aug

Today In Oncology

FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma

Issues in Doctor-Patient Discussions on Potential Harms of Lung Cancer Screening

VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer

Basal Cell Carcinoma and Risk for Development of Other Cancers

Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting

;